DB
ZBIO

Dmitry Balyasny’s Zenas BioPharma ZBIO Stock Holding History

Dmitry Balyasny’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6M Sell
576,717
-90,353
-14% -$1.8M 0.02% 884
2026
Q1 		$13M Buy
667,070
+473,917
+245% +$10.6M 0.02% 901
2025
Q4 		$7.01M Buy
+193,153
New +$6.35M 0.01% 1214

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Dmitry Balyasny's ZBIO Position: Q2 2026 in Review

Dmitry Balyasny reduced its Zenas BioPharma (ZBIO) stake by 14% in Q2 2026, selling an estimated $1.8M and leaving 576,717 shares worth $14.6M. The position accounts for 0.02% of the portfolio, ranked #884.

Dmitry Balyasny first reported a position in ZBIO in Q4 2025 and has held it in 3 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Dmitry Balyasny held 576,717 shares of Zenas BioPharma worth $14.6M as of Q2 2026.
  • Dmitry Balyasny sold 90,353 Zenas BioPharma shares in Q2 2026, an estimated $1.8M.
  • Zenas BioPharma made up 0.02% of Dmitry Balyasny's portfolio in Q2 2026, its #884 holding.
  • Dmitry Balyasny first reported a position in Zenas BioPharma in Q4 2025 and has held it in 3 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.